ReviewPlant biotechnology journal2016
Biomanufacturing of protective antibodies and other therapeutics in edible plant tissues for oral applications.
Review in Plant biotechnology journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 34 citations in OpenAlex.
- Prevention of Shiga toxin 1-caused colon injury by plant-derived recombinant IgA.Scientific reports · 2022Article
- Compendium on Food Crop Plants as a Platform for Pharmaceutical Protein Production.International journal of molecular sciences · 2022Review
- Production of Potyvirus-Derived Nanoparticles Decorated with a Nanobody in Biofactory Plants.Frontiers in bioengineering and biotechnology · 2022Article
- LPS-binding IgG arrests actively motile Salmonella Typhimurium in gastrointestinal mucus.Mucosal immunology · 2020Article
- A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction.Nature communications · 2020Article
- Article
- Plant-derived secretory component forms secretory IgA with shiga toxin 1-specific dimeric IgA produced by mouse cells and whole plants.Plant cell reports · 2019Article
- Efficient production of human interferon beta in the white of eggs from ovalbumin gene-targeted hens.Scientific reports · 2018Article
- Review
- Protection of Human Colon Cells from Shiga Toxin by Plant-based Recombinant Secretory IgA.Scientific reports · 2017Article
- Plasma-Derived Polyreactive Secretory-Like IgA and IgM OpsonizingFrontiers in immunology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although plant expression systems used for production of therapeutic proteins have the advantage of being scalable at a low price, the downstream processing necessary to obtain pure therapeutic molecules is as expensive as for the traditional Chinese hamster ovary (CHO) platforms. However, when edible plant tissues (EPTs) are used, there is no need for exhaustive purification, because they can be delivered orally as partially purified formulations that are safe for consumption. This economic benefit is especially interesting when high doses of recombinant proteins are required throughout the treatment/prophylaxis period, as is the case for antibodies used for oral passive immunization (OPI). The secretory IgA (SIgA) antibodies, which are highly abundant in the digestive tract and mucosal secretions, and thus the first choice for OPI, have only been successfully produced in plant expression systems. Here, we cover most of the up-to-date examples of EPT-produced pharmaceuticals, including two examples of SIgA aimed at oral delivery. We describe the benefits and drawbacks of delivering partially purified formulations and discuss a number of practical considerations and criteria to take into account when using plant expression systems, such as subcellular targeting, protein degradation, glycosylation patterns and downstream strategies, all crucial for improved yield, high quality and low cost of the final product.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.